Abstract The upregulation or mutation of C-MYC has been observed in gastric, colon, breast, and lung tumors and in Burkitt's lymphoma. However, little is known about the role C-MYC plays in gastric adenocarcinoma. In the present study, we intended to investigate the influence of C-MYC on the growth, proliferation, apoptosis, invasion, and cell cycle of the gastric cancer cell line SGC7901 and the gastric cell line HFE145. C-MYC cDNA was subcloned into a constitutive vector PCDNA3.1 followed by transfection in normal gastric cell line HFE145 by using liposome. Then stable transfectants were selected and appraised. Specific inhibition of C-MYC was achieved using a vector-based siRNA system which was transfected in gastric cancer cell line SGC7901. The apoptosis and cell cycles of these clones were analyzed by using flow cytometric assay. The growth and proliferation were analyzed by cell growth curves and colony-forming assay, respectively. The invasion of these clones was analyzed by using cell migration assay. The C-MYC stable expression clones (HFE-Myc) and C-MYC RNAi cells (SGC-MR) were detected and compared with their control groups, respectively. HFE-Myc grew faster than HFE145 and HFE-PC (HFE145 transfected with PCDNA3.1 vector). SGC-MR1, 2 grew slower than SGC7901 and SGC-MS1, 2 (SGC7901 transfected with scrambled control duplexes). The cell counts of HFEMyc in the third, fourth, fifth, sixth, and seventh days were significantly more than those of control groups (P \ 0.05). Those of SGC-MR1, 2 in the fourth, fifth, sixth, and seventh days were significantly fewer than those of control groups (P \ 0.05). Cell cycle analysis showed that proportions of HFE-Myc and SGC-MR cells in G0-G1 and G2-M were different significantly with their control groups, respectively (P \ 0.05). The apoptosis rate of HFE-Myc was significantly higher than those of control groups (P \ 0.05). Results of colony-forming assay showed that the colony formation rate of HFE-Myc was higher than those of control groups; otherwise, the rate of SGC-MR was lower than those of their control groups (P \ 0.05). The results of cell migration assay showed that there were no significant differences between experimental groups and control groups (P [ 0.05). In conclusion, C-MYC can promote the growth and proliferation of normal gastric cells, and knockdown of C-MYC can restrain the growth and proliferation of gastric cancer cells. It can induce cell apoptosis and help tumor cell maintain malignant phenotype. But it can have not a detectable influence on the ability of invasion of gastric cancer cells.
Introduction
Globally, gastric cancer is the second most common malignancy. Although the incidence of the disease has been declining for the past few decades, each year, roughly 798,000 people are diagnosed with gastric cancer worldwide (9.9% of total cancer cases), and 628,000 people die from the disease (12.1% of cancer deaths) [1] . In China, gastric cancer is the most common carcinoma. A variety of factors can affect the complex multi-factorial and multistage process of gastric carcinogenesis [2] [3] [4] . Some researchers have reported that C-MYC gene can play a very important role in gastric carcinogenesis. C-MYC protooncogene is one of the most frequently activated oncogenes, and is estimated to be involved in 20% of all human cancers, affecting about 100,000 US cancer deaths per year [5, 6] . The cancer deaths concerned with this gene in China is still not clear. It is therefore critical that the functions of C-MYC in gastric cancer and other cancers are well delineated.
C-MYC gene is an important member of MYC protooncogene family. The oncogene MYC family encodes the transcription factor proteins N-myc, c-myc, and L-myc which are implicated in the regulation of cell proliferation and differentiation [7, 8] , and apoptosis [9, 10] . N-myc, cmyc, and L-myc are also widely expressed in developing and adult tissues and organs, which are also involved in neoplasia. The C-MYC oncogene (located at chromosomal band 8q24) encodes a transcriptional factor that regulates a variety of genes related to proliferation, differentiation, and apoptosis [11] . The C-MYC protein is a transcription factor which regulates a large series of downstream genes.
Some studies have shown an association between C-MYC deregulation and gastric cancer. C-MYC overexpression has been described in over 40% of GC [12] . Calcagno et al. [13] reported that C-MYC protein was expressed in all cases of both intestinal-and diffuse-type gastric adenocarcinoma samples of individuals from Northern Brazil. Kozma et al. [14] and Yang et al. [15] reported that higher C-MYC expression was associated with the presence of metastasis. Onoda et al. [16] also found that C-MYC mRNA levels were higher in metastatic than in primary lesions. Han et al. [17] described that patients with high levels of C-MYC expression had poor disease-free survival. Therefore, its expression may represent an aggressive phenotype of GC. The gene overexpression has also been seen in early GC when tumor invasion is confined to the mucosa or submucosa regardless of the presence of lymph node metastasis [17] [18] [19] [20] [21] . Xu et al. [22] noticed that C-MYC protein expression increased progressively from chronic active gastritis, gastric ulcer, and mild nonclassic proliferation to progressive GC. Lan et al. [23] found that C-MYC expression was higher in GC than in chronic gastritis, intestinal metaplasia, and dysplasia. In one word, the results of these researches above mentioned have suggested that C-MYC could enhance the canceration of gastric epithelial cells.
To date, most of these studies have been carried out on human gastric cancer tissues while the relationship between C-MYC and parameters of tumor cell proliferation has not been studied much or well characterized. Therefore, we have chosen to study C-MYC function in tumor cells, using the gene transfection and the RNAi technique that allows specific upregulation and downregulation of C-MYC gene expression to determine what role, if any, this protein has in contributing to the biological activity of transformed cells. We have used a human gastric cancer cell line SGC7901 and a human normal gastric cell line HFE145 to analyze the role of C-MYC. We report that C-MYC expression is crucial for tumor cell growth, survival, and the maintenance of tumor cell parameters that may contribute to malignant potential.
Materials and methods

Materials
C-MYC monoclonal antibody was purchased from Abcam Company (Cambridge, MA, USA), Rabbit antimouse HPR (1:1,000; Dako, Copenhagen, Denmark) was used to recognize corresponding proteins. PCDNA3.1 vector was preserved by our laboratory; common cell culture plates were purchased from Orange Company (Belgium). Transwell cell culture plates were purchased from Castar Company, and Watrigel gel was purchased from BD Company (USA). AnexinV-FITC apoptosis detection kit was purchased from Biosea Biotechnology Co., Ltd (Beijing, China). All the primers used in this research were synthesized by Shanghai Boya Biotechnology Co., Ltd (Shanghai, China).
Cell lines and culture
The human gastric adenocarcinoma cell line (SGC7901) was obtained from Shanghai Cell Research Institute of Chinese Scientific Academy, stored and transfer cultured in our laboratory. The human gastric cell line (HFE145) was preserved by our department. DMEM containing 10% calf serum, 100 IU/mL penicillin, and 100 IU/mL streptomycin were used as conventional culture medium. The culture procedures were taken under 37°C, 5% CO 2 , and saturation humidity.
Investigation of C-MYC expression in SGC7901 and HFE145 cell line
The expressions of C-MYC in SGC7901 and HFE145 were detected to determine whether the cell lines could use in the research. RT-PCR and immunocytochemical assay were performed to detect the expression of C-MYC in cells, and the results showed that there was a high expression level of C-MYC in SGC7901 cell, but HFE145 was a C-MYCdefective cell strain. The two cell lines were all suitable for transfection or RNAi experiments, respectively.
Transfections
Human gastric HFE145 cells were transfected with the cDNA of C-MYC gene. For the stable transfections, the cDNA was inserted into the pcDNA3.1 expression vector (Invitrogen, San Diego, CA, USA) between the EcoRI and BamHI sites. The orientation of the insert was confirmed by restriction digestion and DNA sequencing. The pcDNA3.1 vector inserted with C-MYC cDNA was renamed as pcDNA3/MYC which was transfected into HFE145 cells using a Lipofectamine2000 liposome transfection kit (Boehringer Mannheim, Indianapolis, IN, USA). The pcDNA3.1 empty vector transfection group and the blank control group (only liposome was added, and there was no vector DNA transfected) were established. Putative transfectants were then selected by antibiotic resistance in cell culture medium containing 800 lg/ml G418. After 6 weeks of culture in the presence of G4l8, the remaining cells were isolated with cloning cylinders and transferred into 24-well dishes. 17 and 12 clones were, respectively, obtained in the pcDNA3/Myc vector transfection group (HFE-Myc) and pcDNA3.1 empty vector transfection group (HFE-PC). These selected clones were taken for identification and frozen for future use.
C-MYC siRNA synthesis and manipulation
The nucleic acid sequence of C-MYC was obtained from Genbank. OligoEngine software was used to select two targeted fragments for RNAi as follows: 1 0 -CAGCGAGG ATATCTGGAAGAA; 2 0 -CTCCACACATCAGCACAAC TA. These 21 nucleotide DNA sequences were corresponding to C-MYC (Genebank V00568) coding nucleotides.
To control for the specificity of the RNAi effect, an independent DNA duplex was designed and produced, respectively, with 1-point mutations compared with the C-MYC siRNA duplex; this served as the control for the transfection procedure. Scrambled control sequence was as follows: (1) CAGCTAGGATATCTGGAAGAA; (2) CTC CACACATCAGAACAACTA. A BLAST search of the C-MYC siRNA against the Genbank _ EMBL _ DDBJ _ PDB sequences was performed, and the results showed that only one gene, human mRNA encoding the c-myc oncogene (C-MYC), is targeted. BLAST searches of the control siRNA against the same sequences showed no other human gene to be targeted. According to the selected targeted fragments, two C-MYC siRNA duplexes and two scrambled control duplexes were synthesized as follows:
The C-MYC siRNA duplexes: S1 cmy-sh-1F: GATCCGCGAGGATATCTGGAAGAAT TCAAGAGATTCTTCCAGATATCCTCGCTGA cmy-sh-1R: AGCTTCAGCGAGGATATCTGGAAGA ATCTCTTGAATTCTTCCAGATATCCTCGCG S2 cmy-sh-2F: GATCCCCACACATCAGCACAACTATT CAAGAGATAGTTGTGCTGATGTGTGGAGA cmy-sh-2R: AGCTTCTCCACACATCAGCACAACTA TCTCTTGAATAGTTGTGCTGATGTGTGGG Scrambled control duplexes: S1 s cmy-sh-1F: GATCCGCGAGGATATCTGGAAGAAT TCAAGAGATTCTTCCAGATATCCTAGCTGA cmy-sh-1R: AGCTTCAGCTAGGATATCTGGAAGA ATCTCTTGAATTCTTCCAGATATCCTCGCG S2 s cmy-sh-2F: GATCCCCACACATCAGCACAACTATT CAAGAGATAGTTGTTCTGATGTGTGGAGA cmy-sh-2R: AGCTTCTCCACACATCAGAACAACTA TCTCTTGAATAGTTGTGCTGATGTGTGGG All the DNA fragments were chemically synthesized, purified, and annealed by Dharmacon Research (Dharmacon Research, Lafayette, CO, USA) and manipulated according to the manufacturer's instructions. These duplex DNA fragments were inserted into pSliencer TM 4.1-CMV neo vector (Ambion, Austin, Texas, USA), and then vectorbased siRNAs were amplified and verified by DNA sequencing.
Cell culture and RNA transfection SGC7901 cells were grown in DMEM medium (Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum (FCS) without antibiotics. Twenty-four hours before transfection, 1 9 10 6 cells were seeded into a T75 flask in 15 ml DMEM medium with 10% FCS. Lipofectamine2000 liposome transfection kit (Boehringer Mannheim, Indianapolis, IN, USA) was used to transfect short interference RNAs (siRNAs) into cells according to the procedures recommended by the manufacturer. An amount of 1 nmol siRNA duplex was used for each T75 flask. In cases of apparent overconfluence, assessed by simple visual examination, cells were split on the second day after the transfection, but the cells were maintained in various media containing the vector-based siRNA duplexes at the appropriate concentration. All assays were carried out on day 5 after transfection, except the growth curve study, which was initiated on day 2 after the transfection and continued over the subsequent 7 days. Two groups of SGC7901 cell transfected with two siRNA duplexes were renamed as SGC-MR1 and SGC-MR2. Other two groups of SGC7901 cell transfected with scrambled control duplexes were renamed as SGC-MS1 and SGC-MS2, respectively. On the fifth day after transfection, the effect of siRNA on the gene expression was analyzed.
Analysis of transfectants
The RT-PCR and Western blotting analysis were, respectively, performed to detect the mRNA and protein of C-MYC in each sample, and immunocytochemical analysis was used to detect the expression of C-MYC protein in the HFE-Myc and HFE-PC cells in situ. In immunocytochemical analysis, human colorectal cancer cell line SW480 was immunocytochemical detected as positive control [24] , and HFE-Myc cells were immunostained using PBS instead of C-MYC antibody as negative control.
Cell growth curves
All of 17 HFE-Myc cell clones, 12 HFE-PC cell clones, and untreated HFE145 cell were used. The cells of each clone were inoculated into 24-well culture plate at the concentration of 5 9 10 4 /ml. After the cells completely plating, they were washed once with PBS, and then trypsinized in 0.5 ml of Trypsin/EDTA and counted in triplicates at 1-7 days using a cell counter (Beckman Coulter, Inc., Fullerton, CA, USA). The mean values of all of 17 HFE-Myc cell clones and 12 HFE-PC cell clones on different time were calculated, and growth curves were plotted.
Two days after the siRNA transfection, cells of SGC-MR1, 2, SGC-MS1, 2 and untreated SGC7901 groups were trypsinized and seeded at 5 9 10 4 per well in 6-well plates. Subsequently, cells were trypsinized and counted each day after plating.
Colony formation assay
Each clone of HFE-Myc, HFE-PC, and untreated HFE145 groups was detected. 1,000 cells of each clone were, respectively, seeded in a 9-cm cell culture dish. After 18 days' culture in DMEM containing fetal calf serum, cell colonies were then fixed and stained with 0.5% methylene blue (Sigma, Poole, Dorset, UK) in ethanol. All colonies visible by eye with more than 50 cells were counted separately for each sample, and their clone formation rates were evaluated (clone formation rate = number of clones in each dish/1,000). Three reduplicate dishes were used from each clone.
On the fourth day after transfection, 1,000 cells from each sample of SGC-MR1, 2, SGC-MS1, 2 and untreated SGC7901 groups were seeded in 6-well plates and kept growing in 4 ml DMEM with 10% FCS until 14 days after transfection. Cell colonies were then fixed and stained with 0.5% methylene blue in ethanol. All colonies visible by eye were counted separately for each sample, and their clone formation rates were evaluated.
Analysis of cell cycle and apoptosis
All cell clones of HFE-Myc, HFE-PC, and untreated HFE145 groups and all cell samples of SGC-MR1, 2, SGC-MS1, 2 and untreated SGC7901 groups were detected by flow cytometry for analysis of cell cycle and apoptosis. When the cells covered 70% of the area of cell culture plates, serum-free culture medium was used for synchronization. After 24-h continuous culture, the cells were harvested and fixed by 100% ethanol, and then prepared for single cell suspensions. After DNA staining, the cell cycles of the samples were measured on a FACS Calibur cytometer. The analysis software was CellQuest. In cell apoptosis analysis, after synchronization and 24-h continuous culture, the cells were harvested and fixed, PI and AnexinV-FITC double staining was performed, and flow cytometry was used to detect the apoptosis of cells. Three replicate tests on every sample were performed in each group; the average values of these groups were calculated, respectively, and comparison between these groups was conducted.
Cell migration assay
Cell migration assays were performed using FCS-coated polycarbonate filters (8 lm pore size; Transwell, BectonDickinson, Franklin Lakes, NJ, USA). The membrane undersurface was coated with 200 ll FCS for 1 h at 37°C and blocked with 200 ll migration buffer (0.5% BSA in DMEM) for 30 min at 37°C. The lower chamber was filled with 500 ll of migration buffer, following which cells were plated in the upper chamber of four wells per treatment at a density of 1 9 10 5 in 100 ll of migration buffer and incubated at 37°C for 4 h. Following incubation, cells in the upper compartment were trypsinized and counted by the CASY 1 counter (Sharfe System, Reutlingen, Germany). Cells that had migrated to the lower surface of the filter were also trypsinized and counted. The migration rate was obtained by dividing the cell number in the lower chamber by the sum of the cell number found in both the lower chamber and the upper chamber.
Results
Expression of C-MYC gene in SGC7901 and HFE145 cell lines
The expression of C-MYC gene in gastric adenocarcinoma cell strain SGC7901 and gastric cell strain HFE145 were detected by RT-PCR and immunocytochemical analysis. All the results in HFE145 cell strain were negative, which indicated that there was no detectable expression of C-MYC gene in untreated HFE145 cells. On the other hand, the results in SGC7901 cell strain were positive. The results of immunocytochemical assay showed that the expression of C-MYC gene in SGC7901 cells was mainly distributed in nucleus and cytoplasm, and there was no obvious positive signal in cell membrane (Figs. 1, 2) .
Expression of C-MYC gene in transfectants
The results of RT-PCR, western blotting, and immunocytochemical analysis showed that the expression of C-MYC gene significantly increased in HFE-Myc cells when compared with the untreated HFE145 cells or HFE-PC cells, respectively. On the other hand, the results of immunocytochemical assay showed that the expression of C-MYC gene in HFE-Myc cells was mainly distributed in cytoplasm and nucleus (Figs. 3, 4, 5) . The results of RT-PCR and western blotting showed that C-MYC siRNA can efficiently and specifically decrease endogenous C-MYC expression. As shown in Figs. 6 and 7 , only the C-MYC siRNA caused the downregulation of C-MYC protein, while C-MYC protein levels in the scrambled siRNA and untreated control samples showed no significant change. These results indicate that only specific siRNA caused complementary mRNA degradation and thus the decrease of the corresponding protein (Figs. 6, 7) .
The influence of C-MYC gene on cell growth
The results of cell growth curve assay showed that HFEMyc cells grew significantly faster than HFE-PC and untreated HFE145 cells, respectively (P \ 0.05), and there , respectively, which were significantly more than those of the two control groups (P \ 0.05) (Fig. 8a) .
The growth curves of SGC-MR1, SGC-MR2, SGC-MS1, SGC-MS2, and untreated SGC7901 (Fig. 8b) groups showed that treatment with C-MYC siRNA, but not with scrambled siRNA, could restrain cell growth over a period of 7 days. On days 4, 5, 6 and 7 after inoculation, the average cell counts of SGC-MR1 group were 1.35 9 10 5 , 2.02 9 10 5 , 2.51 9 10 5 , and 2.86 9 10 5 , respectively, which resembled those of SGC-MR2 group and were significantly fewer than those of the control groups (P \ 0.05).
The influence of C-MYC gene on colony formation
The clone formation rates of the HFE-Myc (0.27 ± 0.04) were significantly higher than that of their control groups, respectively (P \ 0.05). There was no significant difference between these control groups (P [ 0.05) (Fig. 9a) . It is apparent that transfection with C-MYC gene increased the capacity of these cells to establish colonies to a highly significant degree.
An example of data from a colony-forming assay for SGC-MR cells is shown in Fig. 10b which was significantly lower than that of their control groups, respectively (P \ 0.05) (Fig. 9b) . It is apparent that transfection with C-MYC siRNA decreased the capacity of these tumor cells to establish colonies.
C-MYC is important for cell cycle progression
The results of the effect of C-MYC on individual experiments measuring cell cycle progression were summarized in Tables 1 and 2 . It was clear that upregulation or downregulation of C-MYC gene expression led to consistent changes in the number of cells in G0/G1, S, and G2/M phase.
The influence of C-MYC gene on cell apoptosis
The apoptosis assay results showed that the average apoptosis rates of all cell clones in HFE-Myc, HFE-PC and untreated HFE145 groups were 5.81 ± 0.71, 2.96 ± 0.56, horizontal axis was the number of days Fig. 7 The western blot results of C-MYC in SGC-MR1, SGC-MR2, SGC-MS1, SGC-MS2, and untreated SGC7901 cells. S R1 and S R2 were the results of western blot for C-MYC and b-actin control in SGC-MR1 and SGC-MR2 cells, respectively; S S1 and S S2 were the results of western blot for C-MYC and b-actin control in SGC-MS1 and SGC-MS2 cells, respectively. S was that in untreated SGC7901 cell. The results showed that the expression level of C-MYC gene in SGC-MR1 and SGC-MR2 cells was decreased when compared with the control groups Fig. 9 The results of colony formation assay for C-MYC-transfected and C-MYC-RNAi cell lines. a The results of colony formation assay of HFE-Myc, HFE-PC and HFE145 cells. 1 the colony formation rate of HFE-Myc cell, 2 that of HFE-PC cell, 3 that of HFE145 cell line. b The results of colony formation assay of SGC-MR1, SGC-MR2, SGC-MS1, SGC-MS2, and untreated SGC7901 cell lines. 1, 2 the colony formation rate of SGC-MR1, SGC-MR2 cells, respectively; 3, 4 that of SGC-MS1, SGC-MS2 cells, respectively; 5 that of SGC7901 cell line and 2.63 ± 0.35%, respectively, and there was statistical significant difference between HFE-Myc and their control groups (P \ 0.05). The results of apoptosis assay in SGC-MR1, SGC-MR2, SGC-MS1, SGC-MS2, and untreated SGC7901 groups were 2.63 ± 0.24, 2.44 ± 0.16, 2.25 ± 0.32, 2.56 ± 0.27, and 1.99 ± 0.37%, respectively, and there was no statistical significant difference between them (P [ 0.05). It appeared that upregulation of C-MYC gene expression had an important influence on cell apoptosis.
Role of C-MYC in cancer cell migration
Because individual cell migration is an important characteristic of invasive tumor cells or others, we examined the effects of C-MYC modulation on migration. The migration rates of HFE-Myc, HFE-PC, untreated HFE145 cells, and C-MYC siRNA transfected cells were showed in Fig. 10 . Unfortunately, we were unable to observe statistically significant migration differences in the experimental groups and their control groups (P [ 0.05).
Statistical analysis
In present research, the data were expressed as mean ± SD. One-way ANOVA test and Student's t test were performed. Obtained data were analyzed using SPSS 11.0 (SPSS, USA) statistical software package; Statistical significance was defined as P \ 0.05.
Discussion
Gastric cancer remains a common disease worldwide, with a poor prognosis and low survival rates. Its molecular controls are poorly understood, and the involvement of a number of different cell death or proliferation-modifying genes has been proposed. Among these genes, dysregulation of the transcription factor C-MYC is characteristic of gastric adenocarcinoma as well as other malignancies. C-MYC affects diverse roles in regulating critical biological functions including cell-cycle regulation, apoptosis, metabolism, cellular differentiation, cell adhesion, promotion of neovascularization, and others [5, [25] [26] [27] .
In the present study, cell growth and proliferation was significantly increased in C-MYC-transfected normal gastric cells and significantly decreased in C-MYC-RNAi gastric cancer cells. The results of the present study provide more support for an oncogenic (proliferative) role in gastric cancer and concur with those of Langlois et al. [28] , who also recorded c-myc expression in association with higher mitosis. C-MYC is also well known for the direct and indirect regulation of cellular genes involved in transcription and the mitotic program as well as mediating nuclear events associated with growth factor stimulation [29] [30] [31] . In conclusion, the molecular and biologic factors that control the balance between cell proliferation and apoptosis in development and progression of gastric cancers are complex, but the changes of C-MYC gene expression have an effective influence on growth and proliferation of gastric cancer cell. The results of cell cycle assay suggested that upregulation of C-MYC expression could increase the cells in G2/M stage significantly; otherwise, downregulation of C-MYC expression decreased the proportion of cell in G2/M stage. Our results showed that upregulation of C-MYC expression could reduce the number of cells in S-phase while downregulation of C-MYC expression could increase it. Kristin et al. [32] has conformed that c-Myc overexpression in primary human fibroblasts markedly accelerates S-phase while c-Myc deficient fibroblasts exhibit a prolonged S-phase by detecting the duration of S-phase of mammalian cells when the expression of C-MYC increased and decreased. According to their results, we speculated that lesser cells in S-phase could be found because more cells came into G2/M from S-phase for a shorter duration of S-phase. On the other hand, more cells in S-phase also could be detected for a longer duration of S-phase of c-Myc-deficient cell. These results provided more support for C-MYC's role of promoting cell growth and proliferation. Many investigators have uncovered target genes that encode proteins that regulate the cell cycle. The genes that consistently emerge and contain E-boxes bound by c-Myc in ChIP assays are cyclins D1 and D2, CDK4, and cyclin B1 [33] [34] [35] . Cyclin A, cyclin B, and cdk4 were also identified as MYC targets in Drosophila [36] . It is notable that in vivo genetic studies have implicated a role for CDK4 in C-MYC-mediated transformation [37] . A role for D-type cyclins is more controversial. However, it has been shown that fibroblasts lacking cyclins D1-D3 fail to be transformed by c-Myc, suggesting an important role for D-type cyclins in C-MYC-mediated transformation [38] . C-MYC represses the CDK inhibitors p21 and p15INK4A through an interaction with the Miz-1 protein at the core promoter [39] [40] [41] . In essence, C-MYC directly regulates genes involved in cell cycle regulation.
By cell apoptosis assay, we found that upregulation of C-MYC expression could increase the cell apoptosis rate in gastric cell line. It is seemed that C-MYC could induce gastric cell apoptosis, but the results of many researches implied that the influence of C-MYC on cell apoptosis was very complex, and there were contradictory conclusions in their reports. Other in vitro experiments show that stable transfection of C-MYC and subsequent protein activation in low C-MYC-expressing melanoma cell lines is able to sensitize these cells to apoptosis under multiple types of stress [42] . The deregulated expression of C-MYC also induces genes that contribute to apoptosis under nutrient or growth factor deprivation; however, C-MYC target genes involved in apoptosis remain to be fully elucidated. A number of excellent reviews are available on C-MYC and apoptosis [10, 43, 44] . The downregulation of C-MYC expression by specific RNAi could have no detectable influence on gastric cancer cell apoptosis. The reason could be that the change of cell apoptosis had not been displayed in the short experimental time. The further research must be needed to confirm the result.
Our results showed that upregulation or downregulation of C-MYC expression could have no influence on cellular migration, so the gene could not impact invasion of gastric cancer cell. The mechanism by which C-MYC impacts cellular migration in gastric cancer is entirely unknown at present. The change of genes that encode cytoskeletal and cell adhesion proteins by C-MYC may contribute to neoplastic transformation and invasion of susceptible cell lines [45, 46] . The altered expression of cytoskeletal genes also influences cellular morphology or invasion ability. For example, C-MYC null fibroblasts possess many actin stress fibers and focal adhesions as compared to null fibroblasts reconstituted with C-MYC [47] . A proteomics approach identified the cytoskeletal proteins actin and cdc42 as downregulated in C-MYC reconstituted fibroblasts. These changes suggest that C-MYC plays a role in enhancing fibroblast motility. These researches suggested that C-MYC could promote cancer cell invasion, but it affects individual gastric cancer cell migration and such possibilities currently are under investigation.
In general, the positive immunohistochemical staining of C-MYC as a transcription factor can be detected in nucleus. But in our research, the positive staining was located in cytoplasm and nucleus. In fact, the results of many researches have suggested that nuclear and cytoplasmic C-MYC staining was common in many human tissue or cell. Geisler et al. [48] reported that C-MYC cytoplasmic staining was present in 75.2% of the tumors, and nuclear staining was present in 66.9% in 121 patients suffering with endometrial carcinoma. Ruzinova et al. [49] also found that nuclear and cytoplasmic C-MYC staining was common in B-cell Lymphomas, and a primarily nuclear or mixed nuclear and cytoplasmic staining pattern for C-MYC could be highly predictive of a C-MYC translocation in the disease. It is well known that C-MYC protein is synthesized in cytoplasm. The synthesis of of C-MYC protein could increase uncommonly in some tumor cells or the cells transfected with C-MYC gene, and C-MYC protein could accumulate in cytoplasm, so cytoplasmic c-myc staining should be possible.
Conclusion
The results of the present investigation demonstrated that overexpression of C-MYC gene can influence some biological characteristics of normal gastric cell. C-MYC can promote the growth and proliferation of these cells and help tumor cell maintain malignant phenotype. But it can have a negative influence on the ability of invasion of gastric cancer cells. Specific knockdown of C-MYC can reduce gastric cancer cell growth and proliferation, so the gene could be a potential target of gene therapy.
